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The first famihes with a tendency to venous thrombosis were re-
ported m the early 1900s (1) In 1965, Egeberg reported a family with
throrabophiha and an identified hereditary defect (antithrombm defi-
ciency) (2) In the early 1980s, deficiencies of other natural anticoagu-
lants - protem C and protem S - were shown to be associated with
venous thrombosis m famihes with famihal thrombophiha (3, 4)
Recently, several other blood abnormahties have been descnbed that
mcrease the nsk of thrombosis resistance to activated protem C,
usually the result of a mutation in factor V (factor V 1691A or f actor V
Leiden), a mutation m the prothrombm gene (PT20210A), and high
levels of clottmg factor VIII (5-8)
There are several major differences between the deficiencies of
natural anticoagulants äs nsk factors for thrombosis, and these more
recently descnbed abnormahties First, biochemically, the deficiencies
all lead to "loss of function" The mutated allele does not lead to any
protem synthesis, or to a non-functional vanant, with a resultant loss of
anticoagulant activity, and an mcreased nsk of thrombosis The vanant
protem that is the result of the 1691 G~>A mutation (tactor V Leiden),
however, displays "gam of function" the molecule has become re-
sistant to mactivation by activated protem C, its mcreased function leads
to an mcreased thrombotic nsk Similarly, although here the mecha-
msm is less clear, the prothrombm mutation, at the l'-untranslated end
of the gene, is associated with elevated levels of prothrombm These, m
turn, are associated with mcreased nsk of thrombosis High levels of
factor VIII are also hkely to be expressions of gam m function A
second charactenstic that differentiates these "gam-of function" abnor-
mahties from the deficiency defects is their high prevalence As is
shown m the table, the prevalences m the general population of the
Netherlands vary between 2 and 11 percent, while deficiencies of pro-
tem C, protem S and antithrombm are only found in a tew per thousand
or less (9-11) A third difference is that "gain-of-function"abnormah-
ties tend to be less strong nsk factors than "loss of-function"mutations
while for the latter relative nsks are around 10 for heterozygous camers
(relative to normal mdividuals), prothrombm 20210A and factor V Lei
den mcrease the nsk 3-8 fold For high levels of factor VIII such com-
pansons are less straightorward smce they depend on the cut-off value
that is used, but at the cut-off value of 150IU/dl the abnormality is also
prevalent and of moderate strength Even though the nsk mcrease may
be less for the "gam-of-function" abnormahties, they are much more
important than the deficiencies from a public health pomt of view (9)
The proportion of thrombosis caused by a nsk factor (attnbutable nsk)
depends on the relative nsk and the number of people this risk apphes
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to, i e, the prevalence As the table shows, a sizable proportion of all
thrombotic events can be attnbuted to factor V Leiden, prothrombm
2021OA and high levels of factor VIII - obviously, smce these figures
refer to the population, they are population-specific, and will differ
between populations with different prevalences
High levels of factor VIII were associated with an mcreased nsk of
thrombosis m the Leiden Thrombophiha Study (LETS) (8) Individuais
with levels of factor VIIIC exceeding 150 ILJ/dl had a 3-fold mcreased
risk compared to those with levels below 150IU/dl and a 6-fold m-
creased nsk compared to those with levels below lOOIU/dl Arguments for
this association to be causal were found m the "dose-response" relation
between factor VIII levels and thrombosis, and in the findmg that
while blood group (non-0 vs 0), levels of von Willebrand factor and
factor VIII levels each mcreased the risk of thrombosis m umvanate
analysis, only factor VIII levels remamed äs a strong nsk factor when
these three variables were mutually adjusted for (8) This study cor-
roborated and explamed fmdings of 25 years before, le the report of Jick
et al of the association between ABO blood group and the nsk of throm-
bosis (12) Factor VIII levels which are to a large extent determmed by
blood group and von Willebrand factor levels appeared the effector of
the thrombotic nsk (8) While ABO blood group has been known äs a
determmant of factor VIII levels for many years (13,14), this analysis
mdicated that there were other factors affectmg the factor VIII levels
Studies among women m whom factor VIII was measured to rule out
hemophilia carnership (15), äs well äs among famihes with thrombo-
phiha (16), showed that factor VIII levels are affected by famihal
factors other than blood group Until now, however, attempts to find
genetic vanants associated with factor VIII withm the factor VIII gene
havefailed(17)
Two reports m this issue of Thrombosis and Haemostasis deal with
factor VIII levels äs a nsk factor for venous thrombosis, and they
contam several important fmdings (18, 19) First of all, the paper by
Kraaijenhagen et al (18) confirms that high factor VIII levels mcrease
the nsk From their report it follows that levels exceeding 150 lU/dl
mcrease the nsk over 5-fold compared to levels below 100 lU/dl, which
is m agreement with the results from the LETS study (8) By a family
study they can also confirm that factor VIII levels withm famihes cor-
relate This paper, and the paper by O'Donnell et al (19) shows that
high levels of factor VIII very often persist over time For factor VIII
levels determmed by blood group this is fully expected, but O'Donnell
et al also show that these high levels were not secondary to high von
Willebrand levels, ιέ, these data also suggest a persistent, probably
genetic, ongm of high levels of factor VIII beyond the vWF-mediated
blood group effects O'Donnell et al have previously shown that high
factor VIII levels are hkely to be a cause of an mcreased thrombotic nsk
rather than a consequence, smce adjustment for acute phase reactants
(CRP, fibrmogen) did not lead to attenuation of the nsk estimate (20)
Similar results were obtamed m the Leiden Thrombophiha Study (21)
l
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Table I Prevalence and populaton attnbutable risk ot two types of prothrom-
botic abnormalities'
population prevalence population attnbutable nsk
lo VA oj ßmctjon
protem C deficiency 02 2
protein S deficiency <12 <\
antithrombin deficiency 0 02 <1
gaitt offimctwn
factor V Leiden 4 25
prothrombm 2021 OA 2 4
high levels of factor VIII1 U 16
1 Figures may differ for vanous populations 2 Rehable population estimates for protem S
deficiency are missmg ' Levels exceedmg 150 lU/dl
and are agam confirraed m the present studies Probably the strengest
argument m this debate is the association between blood group and
venous thrombosis, since blood group is invariant Nevertheless, none
of these findmgs can completely rule out the possibility of post-hoc
factor VIII elevation or an effect of blood group on venous thrombotic
nsk that is not mediated by factor VIII It will be important to see
whether high levels of factor VIII are, äs other types of thrombophilia,
associated with mcreased thrombin generation Ongomg research will
focus on the genotypes underlymg high levels of factor VIII
Is there any clmical relevance to this, and should we screen for high
levels of factor VIII m a thrombophilia work-up, or perhaps in all
patients with thrombosis9 This is a question we may m fact ask for all
thrombophilia screenmg, since the therapeutical consequences of a
diagnosis are unclear It is noteworthy that, contrary to factor V Leiden
(22), high levels of factor VIII do not mteract synergistically with the
use of oral contraceptives (23), so that screenmg pnor to subscnbmg
oral contraceptives would not even offer a theoretical benefit The
paper by Kraaijenhagen, äs well äs recent other data suggest that high
levels of factor VIII mcrease the nsk of recurrencies of thrombosis (24),
which may pomt to the need for sustamed anticoagulant treatment m
these individuals A major research goal, which will assist us in settmg
rational chmcal policies, is to find out the ongm of elevated levels of
factor VIII
References
1 Schnitzler J Über konstitutionelle und konditionelle Mitbedingtheit post
operativer Vorkommnisse Wien Kim W Sehr 1926,1 26
2 Egeberg 0 Inhented antithrombin deficiency causing thrombophilia
Thromb Diath Haemorrh 1965, 13 516-30
3 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C Deficiency of
protein C in congemtal thrombotic disease J Clm Invest 1981, 68 1370 3
4 Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH Plasma
protein S deficiency in familial thrombotic disease Blood 1984, 64
1297-1300
5 Dahlback B, Carlsson M, Svensson PJ Familial thrombophilia due to a
previously unrecognised mechamsm charactenzed by poor anticoagulant
response to activated protein C prediction ot a cotauor to activated
protein C Proc Natl Acad Sei USA 1993,90 1004 8
6 Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ
De Ronde H, Van der Velden PA, Reitsma PH Mutation m blood coagula-
tion factor V associated with resistance to activated protein C Nature 1994
369 64 7
7 Poort SR, Rosendaal FR, Reitsma PH, Bertma RM A common genetic
Variation m the 3' untranslated region of the prothrombm gene is associated
with elevated plasma prothrombm levels and an mcrease m venous throm
bosis Blood 1996, 88 3698703
8 Koster T, Blann AD, Briet E, Vandenbroucke JP Rosendaal FR Role of
clottmg factor VIII m effect of von Willebrand factor on occurrence of
deep-vem thrombosis Lancet 1995, 345 152-5
9 Rosendaal FR Risk factors for venous thrombotic disease Thromb
Haemostl999,82 610-9
10 Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA
Bertina RM Prevalence of protein C deficiency m the healthy population
Thromb Haemost 1995, 73 87-93
11 Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA
Carrell RW Prevalence of antithrombin deficiency m the healthy popu
lation BrJHaematol 1994,87 106 12
12 Jick H, Slone D, Westerholm B, Inman WHW, Vessey MP, Shapiro S
Lewis GP, Worcester J Venous thromboembolic disease and ABO blood
type Lancet 1969, i 539-42
13 Gill JC, Endres Brooks J, Bauer PJ, Marks WJ, Montgomery RR The
effect of ABO blood groups on the diagnosis ot von Willebrand disease
Blood 1987, 69 1691-5
14 Weis HJ, Sussman I, Hoyer LW Stabihzation of factor VIII m plasma by
the von Willebrand factor J Clm Invest 1997, 60 390-404
15 Kamphmsen PW, Houwmg Duistermaat JJ, van Houwelmgen JC Elken
boom JCJ, Bertina RM, Rosendaal FR Familial clustenng of factor VIII
and von Willebrand factor levels Thromb Haemost 1998, 79 323-7
16 Kamphuisen PW, Lensen RPM, Houwmg Duistermaat JJ, Elkenboom JCJ,
Harvey M, Bertina RM Rosendaal FR Hentability of elevated factor VIII
antigen levels m famihes with thrombophilia Thromb Haemost 1999, 82
(abstract) 4189
17 Mansvelt EPG, Laffan M, McVey JH, Tuddenham EGD Analysis öl the
F8 gene m individuals with high plasma factor VIIIC levels and associated
venous thrombosis Thromb Haemost 1998,80 561 5
18 Kraaijenhagen RA, m 't Anker ES, Koopman MMW, Reitsma PH Pnns
MH, van den Ende A, Buller HR High plasma concentration of tactor VIIIc
is a major risk factor for venous thromboembohsm Thromb Haemost 1999
83 59
19 O'Donnell J Mumford AD, Mannmg RA, Laffan M Elevation ot FVIII m
venous thromboembohsm is persistent and mdependent ot the acute
phase response Thromb Haemost 1999, 83 10-3
20 O'Donnell J, Tuddenham EGD, Mannmg R, Kemball-Cook G Johnson D,
Laffan M High prevalence of elevated FVIII levels m patients reterred for
thrombophilia screenmg role of mcreased synthesis and relationship to the
acute phase reaction Thromb Haemost 1997 77 825-8
21 Kamphuisen PW, Elkenboom JCJ Vos HL Pablo R Sturk A, Bertina, RM
Rosendaal FR Increased levels ot factor VIII and fibrmogen m patients
with venous thrombosis are not caused by acute phase reactions Thromb
Haemost 1999, 81 6803
22 Vandenbroucke JP Koster T Bnei E Reitsma PH Bertina RM, Rosendaal
FR Increased nsk ot venous thrombosis m oral-eoniraceptive users who are
carners of factor V Leiden mutaiion Lant.ei 1994 344 1453-7
23 Bloemenkamp KWM Heimerhorst FM Rosendaal FR Vandenbroucke JP
Venous thrombosis orakontraceptnesandhigh lattorVIII levels Thromb
Haemost 1999 82 1024 7
24 Eichmger S Mmar E Hirsthl M Bulon/ivk C Stam M, Schneider B,
Speiser W LechnerK KvrlePA The nsk öl earl^ recurrent venous throm
boembohsm (VTE) m patienis vmh mueased lauor VIII C (FVIII) and a
first episode ot sponianeous VTE Thromh Haemost 1999, 82 (abstract)
5-6
